Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Propanc Biopharma ( (PPCB) ) has issued an announcement.
On July 25, 2025, Propanc Biopharma, Inc. entered into a securities purchase agreement with an investor to sell a convertible promissory note worth $112,350 for $107,000. The proceeds will be used for general working capital. The note, convertible into common stock after 180 days, has a maturity date of April 30, 2026, and an interest rate of 22% per annum. The agreement includes specific conditions and events of default, impacting the company’s financial operations and obligations.
More about Propanc Biopharma
Propanc Biopharma, Inc. operates in the biopharmaceutical industry, focusing on the development of cancer treatments. The company primarily works on developing novel therapies for the treatment of solid tumors, with a market focus on improving patient outcomes in oncology.
Average Trading Volume: 3,036
Technical Sentiment Signal: Sell
Current Market Cap: $66.28M
For an in-depth examination of PPCB stock, go to TipRanks’ Overview page.